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Introduction: Breast cancer (BC) is one of the leading causes of death among women worldwide.
Immunostimulatory treatment has increasingly been used as adjuvant therapy in the last few years, in patients with
melanoma and other cancer forms, often with an induction of autoimmunity as a consequence of a successful
treatment. We aimed at investigating if coexisting autoimmune diseases (AD) or hypersensitivities (HS) similarly to
the side effects of immunostimulatory treatment resulted in a better overall survival, compared to patients without
these disorders.
Material and methods: The patient material used was a consecutive clinical material consisting of 1705 patients
diagnosed with BC between 1980 and 2010 in Sweden. The patients were stratified according to coexisting AD,
HS or lack of both. Overall survival was calculated using Kaplan-Meier and the Cox proportional hazard model.
Results: Our main finding was that BC patients with estrogen receptor (ER) negative tumors together with
preexisting AD or HS had a statistically significant better overall survival (HR=0.53; 95% CI= 0.30-0.96) compared
to patients without. Premenopausal BC patients with a coexistence of AD or HS had a better overall survival, but
this was not statistically significant.
Discussion: For patients with premenopausal or ER-negative BC, coexistence with AD or HS was associated with
a better overall survival. Although these findings require validation, and the mechanisms responsible need to be
found, they hint to possible new treatment strategies for BC, especially for those with ER-negative tumors and
potentially for premenopausal patients.
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PremenopausalIntroduction
Immunomodulatory antibodies have been used in phase
III trials on metastatic melanoma to enhance anti-tumor
immunity. One target protein studied in clinical trials
for cancer treatment is Cytotoxic T-Lymphocyte Antigen
4 (CTLA-4). CTLA-4 is expressed on the surface of
upregulated T-cells and has an inhibitory effect on T-cell
activation. CTLA-4 plays an important role in the induc-
tion of tolerance to self-antigens (Sanderson et al. 2005;
Attia et al. 2005). A blockade of CTLA-4 enhances anti-
tumor immune actions and improves survival in metastatic* Correspondence: hakan.olsson@med.lu.se
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in any medium, provided the original work is pmalignant melanoma (Sanderson et al. 2005; Attia et al.
2005; Hodi et al. 2010; Simeone & Ascierto 2012). How-
ever, administration of this anti-CTLA-4 antibody is a
double-edged sword. There is a strong correlation between
the induction of tumor regression and grade 3/4 auto-
immune toxicity. Another well-studied target protein of
this kind is Programmed Death-1 (PD-1). PD-1 is
expressed on activated T-cell and has an inhibitory effect
on the effector phase of the T-cell response. A blockade of
PD-1 has been shown to improve survival in various forms
of stage 4 cancers. Adverse effects are mainly immune sys-
tem related, but not as severe as those observed when
using an anti-CTLA-4 antibody (Brahmer et al. 2012;
Topalian et al. 2012).
Autoimmunity is the failure of an organism to recognize
its own parts as self (Marrack et al. 2001; Atassi &an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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showed that the prevalence of 31 different AD in the
population exceeded 5%. Diseases classified as AD in
that study by Eaton et al. can be seen in Additional file 1:
Table S1 (Eaton et al. 2007). Other conditions with a
dysregulated immune system include asthma and allergies,
which are both examples of HS. In both allergies and
asthma, T-cell immune and inflammatory pathways are
the main participants (Ahmad Al Obaidi et al. 2008;
Cookson 2004; Kumar & Abbas 2007).
The hyperreactivity of the immune system in AD, al-
lergies and asthma could possibly be beneficial for pa-
tients with cancer because of an increased tendency to
attack the tumor cells. The mutated cancer cells have an
altered protein expression and behavior, which enables
the immune system to recognize them as malignant
(Weinberg 2007). Hence, our hypothesis was that pa-
tients with AD or other HS such as asthma and allergies
have a better overall survival rate compared to patients
without AD or HS conditions. We decided to investigate
this using BC as a model.
Cancer incidence among people with AD or HS has been
studied previously, with conflicting results (Vojtechova &
Martin 2009; Van Hemelrijck et al. 2010; Hwang et al.
2012; Hemminki et al. 2012; Turesson & Matteson 2012;
Landgren et al. 2011). Cancer prognosis among the same
patients has not been researched to the same extent and
they focus mainly in specific diseases (Ji et al. 2011). The
aim of this study was to investigate if BC patients with
coexisting AD or HS have a better overall cancer survival
compared to BC patients without these comorbidities.
Material and methods
The study material was a cohort consisting of 1705 pa-
tients diagnosed with BC. Part of the patient material
has been used in previous studies (Ellberg et al. 2012;
Ellberg et al. 2010; Ellberg & Olsson 2011; Jernstrom
et al. 1999). All patients were seen by the same physician
at the Department of Oncology, Skåne University Hos-
pital, Lund. The area of uptake is population-based and
has been estimated to cover 300,000 patients in the
southern parts of Sweden (overall population 1.5 mil-
lion). The period of recruitment spans from Jan 1st 1980
to Dec 31st 2010. All subjects were interviewed through
a standardized questionnaire filled out by the physician.
This questionnaire contained information about date of
birth, comorbidities, BC screening habits, parity, age of
menarche, age of menopause, body mass index (BMI),
ever-use of hormonal replacement therapy (HRT) and
ever-use of oral contraceptive pills (OCP). Tumor stage,
ER-status of the tumor and the date of diagnosis were
gathered from pathological reports and patients’ charts.
Follow-up was performed until Jan 1st 2011 using the
Swedish Civil Register as source. Informed consent wascollected from all patients and the study was approved
by an ethical board in Sweden (No 110–92).
The cohort was split in to three groups based on AD,
HS and non-AD/HS. The criteria of inclusion for each
group were report of having AD of any kind (y/n)
(Additional file 1: Table S1), report of having type 1
HS, eczema or urticaria (y/n) and no report of having
AD or HS, respectively. A fourth group (AD-HS) was
constructed as well including both AD and HS.
Throughout the entire study, the control group to an
analyzed patient group was the corresponding counter-
part of the cohort.
Any thyroid diseases of unspecified etiology found
among recorded comorbidities were handled as follows.
Patients with a reported diagnosis of hypothyroidism,
hyperthyroidism, thyrotoxicosis or thyroiditis were in-
cluded into AD. Patients with a reported diagnosis of
goiters, levothyroxine use and thyroid surgery were ex-
cluded. Diabetes type I was included as an AD in the
study. Diagnosed diabetes with the slightest uncertainty
of type was classified as type II and hence excluded from
the AD group.
ER-status was missing in 580 cases due to the fact that
it was not performed in the clinic at the time of diagno-
sis with the exception of advanced BC. 341 cases were
missing information about screening and out of these
315 were premenopausal. An assumption was made that
none of these patients underwent screening, mainly due
to young age.
We chose to study overall survival with age stratifica-
tion. Other types of survival as breast cancer specific
survival or relative survival were not studied. Two age
cut-offs were used; the first at age 65 years old at time of
BC diagnosis to reduce the influence on mortality due to
comorbidities. The second cut-off was set at 50 years old
at time of BC diagnosis to distinguish between pre- and
postmenopausal. The median age of menopause in this
material was 50 years.
Statistics
All statistical analyses were performed using IBM SPSS
20.0. Overall survival for the AD, HS and AD-HS groups
was estimated using Kaplan-Meier. For the AD-HS
group the Kaplan-Meier analyses were also performed
with stratification based on ER-status and menopausal
status. The distribution was tested using the Log-rank
test.
Hazard Ratios (HR) were calculated using cox propor-
tional hazard. Both the AD and the HS groups were ana-
lyzed separately, adjusted for age at diagnosis of BC only,
then adjusted for age at diagnosis of BC and TNM-stage
and further with each age cut-off added. The AD-HS
group was analyzed with the same adjustments initially
and then adjustment for screening as well. The following
Table 1 Summary of AD and HS diagnoses in the patient
material
a) b)




Reumatoid arthritis 28 Asthma 41
Thyreotoxicosis 16 Allergies 27
Hypothyroidism 15 Eczema 3
Psoriasis 12 Urticaria 1
Hyperthyroidism 8
Ulcerous colitis 8 Total 72
Autoimmune gastritis 6











Systemic lupus erythematosus 1
Wegeners’ granulomatosis 1
Total 125
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size status (Tis, T1, T2, T3, or T4), and positive node sta-
tus (N0, N1, N2, or N3), occurrence of distant metastasis
(y/n) and screening (y/n).
HR for the AD-HS group was calculated in the sub-
groups of patients with ER-positive and ER-negative tu-
mors and postmenopausal and premenopausal BC
patients. Exclusion criteria included confirmed distant
metastasis at diagnosis or carcinoma in situ. Exclusion
criteria were set to reduce positive impact on survival in
the AD-HS group and due to the low number of metas-
tases. Adjustments were initially made for age at BC
diagnosis, secondly age at BC diagnosis and T-stage and
N-stage and finally adjustment for screening was added.
The following variables were used: age at diagnosis of
BC (linear), tumor size status (T1, T2, T3, or T4), and
positive node status (N0, N1, N2, or N3) and screening
(y/n).
All HR were estimated with 95% confidence intervals
(CI). Two-tailed p-values were used for all analyses. A




Out of the 1705 BC patients in this study, 125 (7.3%)
had an AD and 72 (4.2%) had HS (Table 1). At time of
last follow-up 913 (53.5%) out of all patients were de-
ceased. Median age at diagnosis of BC for the study
population was 56.3 years old. Patients with an AD were
somewhat older at diagnosis of BC (median 60.6 years)
and patients with HS somewhat younger at BC diagnosis
(median 53.3 years). A greater part (68.8%) of the BC pa-
tients with AD and a lesser part (54.2%) of the BC pa-
tients with HS had already entered menopause at time
of their BC diagnosis. TNM-stage did not vary greatly
between the groups. Similarly, neither BMI, age at me-
narche, age at menopause, HRT ever-use, nor parity
showed any major differences between the groups. OCP
ever-use was more common in the HS group (60%) than
in the cohort as a whole (40%) (Table 2).
Univariate survival analysis
Overall survival was estimated using Kaplan-Meier.
Stratified analyses were made according to ER-status
and menopausal status using the AD-HS group. Patients
with ER-negative tumors and AD-HS had a statistically
significant better overall survival compared to patients
without (Figure 1a). ER-positive cases with AD-HS had a
non-statistically significant tendency towards better
overall survival (Figure 1b). In premenopausal patients
we found a non-statistically significant tendency towards
better overall survival (Figure 1c). On the contrary, in
postmenopausal patients coexistence of AD or HS didnot affect the overall survival (Figure 1d). All three
groups (AD-HS, AD, HS) analyzed separately had a ten-
dency towards better overall survival, though none of
these results were statistically significant (Figure 2).
Multivariate survival analysis
Patients in the ER-negative subgroup with AD or HS
had a statistically significant better overall survival com-
pared to patients without, adjusted for age at BC diagno-
sis, TN-stage and screening (HR 0.53; CI 0.30-0.96)
(Table 3a). The study did not show any difference in
overall survival in the ER-positive subgroup between pa-
tients with AD or HS and patients without, adjusted for
age at diagnosis of BC, TN-stage and screening (HR
0.98; CI 0.70-1.37) (Table 3a).
In premenopausal BC patients, AD or HS was associ-
ated with a tendency towards better overall survival ad-
justed for at age at BC diagnosis, TN-stage and
screening (HR 0.63; CI 0.38-1.04) (Table 3b). Postmeno-
pausal patients with AD or HS had no tendency towards
better or worse overall survival adjusted for age at BC
diagnosis, TN-stage and screening (HR 1.02; CI 0.77-
1.34) (Table 3b).
Table 2 Patient and tumor characteristics in relation to coexistence of AD or HS
AD HS Non-hypersensitive All
Number of cases 125 72 1508 1705
Age at diagnosis of BC Median (range) 60.6 (31.5-80.4) 53.3 (25.4-82.5) 56.1 (23.6-89.5) 56.3 (23.6-89.5)
BMI Median 24.6 24.1 24.2 24.2
Age at menarche Median 13.0 13.0 13.5 13.5
Age at menopause Median 50.0 50.0 50.0 50.0
Deceased Yes 57 (46%) 30 (42%) 826 (55%) 913 (54%)
T-stage In situ 4 (3%) 5 (7%) 71 (5%) 80 (5%)
1 68 (54%) 36 (50%) 744 (49%) 848 (50%)
2 40 (32%) 23 (32%) 539 (36%) 602 (35%)
3 9 (7%) 8 (11%) 104 (7%) 121 (7%)
4 0 (0%) 0 (0%) 7 (1%) 7 (0.4%)
Unknown 4 (3%) 0 (0%) 43 (3%) 47 (3%)
N-stage 0 54 (43%) 39 (54%) 631 (42%) 724 (43%)
1 44 (35%) 20 (28%) 514 (34%) 578 (34%)
2 17 (14%) 8 (11%) 204 (14%) 229 (13%)
3 5 (4%) 4 (6%) 91 (6%) 100 (6%)
Unknown 5 (4%) 1 (1%) 68 (5%) 74 (4%)
M-stage 0 117 (94%) 71 (99%) 1349 (90%) 1537 (90%)
1 1 (1%) 0 (0%) 24 (2%) 25 (2%)
Unknown 7 (6%) 1 (1%) 135 (9%) 143 (8%)
ER Status Negative 20 (16%) 17 (24%) 321 (21%) 358 (21%)
Positive 70 (56%) 33 (46%) 664 (44%) 767 (45%)
Unknown 35 (28%) 22 (31%) 523 (35%) 580 (34%)
Postmenopausal No 32 (26%) 31 (43%) 490 (33%) 553 (32%)
Yes 86 (69%) 39 (54%) 936 (62%) 1061 (62%)
Unknown 7 (6%) 2 (3%) 82 (5%) 91 (5%)
Screening No 78 (62%) 31 (43%) 934 (62%) 1043 (61%)
Yes 29 (23%) 18 (25%) 274 (18%) 321 (19%)
Unknown 18 (14%) 23 (32%) 300 (20%) 341 (20%)
OCP ever-use Yes 50 (40%) 42 (58%) 625 (41%) 717 (42%)
HRT ever-use Yes 31 (25%) 12 (17%) 277 (18%) 320 (19%)
Parity 0 28 (22%) 15 (21%) 250 (17%) 293 (17%)
1 20 (16%) 15 (21%) 284 (19%) 319 (19%)
2 56 (45%) 23 (32%) 579 (38%) 658 (39%)
3 18 (14%) 10 (14%) 280 (19%) 308 (18%)
4 + 3 (2%) 9 (13%) 115 (8%) 127 (7%)
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coexisting AD or HS had a non-statistically significant
tendency towards better overall survival adjusted for age
at diagnosis of BC (HR 0.88; CI 0.71-1.10). Adding ad-
justment for TNM-stage as well, a better overall survival
effect remained but not statistically significant (HR 0.91;
CI 0.72-1.14). Additional adjustment for screening showeda non-statistically significant tendency towards better
overall survival (HR 0.95; CI 0.74-1.23). Including only pa-
tients younger than 50 years old at BC diagnosis in the
analysis the AD-HS group had a tendency towards a better
overall survival (HR 0.74; CI 0.48-1.16) (Table 4a).
Both the AD and HS groups had a tendency towards
better overall survival when they were analyzed separately
Figure 1 Survival analysis in BC patients with coexistence of AD or HS stratified based on ER- and menopausal status. Kaplan-Meier
analysis on the coexistence of AD or HS stratified based on ER- and menopausal status in; a) patients with ER-negative tumors (dotted line)
(N=36), b) patients with ER-positive tumors (dotted line) (N=96), c) premenopausal patients (dotted line) (N=56), and d) postmenopausal patients
(dotted line) (N=117) compared to BC patients without (whole line). Log-rank tests were performed individually for each Kaplan-Meier analysis
and are presented in each diagram respectively.
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significant.
Discussion
Our aim was to investigate if AD or HS constitute pro-
tective factors for overall survival among BC patients.
This study showed a statistically significant overall sur-
vival benefit for patients diagnosed with an ER-negative
BC if they had a concurrent diagnosis of an AD or a HS.
Premenopausal BC patients with AD or HS had an over-
all survival advantage compared to those without these
comorbidities.
This raises the question of the mechanism behind the
better overall survival for patients with co-existing AD
or HS. As mentioned in the introduction, successful
immunostimulatory therapy is often associated with the
development of an AD. Since the mutated cancer cells
have developed host immune evasion strategies, an over-
active immune system that reacts to self-antigens maydiscover and target cancer cells more readily. From our
study, these benefits were more evident in young patients
and in those ER-negative BC, but were less clear for other
patients.
In most analyses, the difference between the groups
was weakened when adjusted for tumor size, lymph
node involvement and distant metastases. A possible ex-
planation for this might be that patients with AD or HS
had less advanced tumors at time of diagnosis and/or an
effect of exclusion of patients with missing information.
It might also be that coexistence of AD or HS retards or
inhibits tumor progression. Another possible reason is
that patients with AD or HS have closer and more regular
contact with medical health care and therefore the tumors
are found at an earlier stage. Lower mortality observed
among patients with AD or HS may also represent the ef-
fect of a generalized increase in health awareness.
ER-negative BC patients with AD or HS still exhibited
significant overall survival differences even after adjusting
Figure 2 Survival analysis in BC patients with coexistence of AD or HS. Kaplan-Meier analysis on the coexistence of AD or HS in; a) patients
with AD or HS (dotted line) (N=197), b) patients with AD (N=125) (dotted line), and c) patients with HS (dotted line) (N=72) compared to BC
patients without (whole line). Log-rank tests were performed individually for each Kaplan-Meier analysis and are presented in each
diagram respectively.
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adjustment for BC screening was made, since BC found
through screening has a better prognosis due to earlier de-
tection (Nystrom et al. 2002). Among patients with ER-
negative tumors, screening detection did not weaken the
result. This indicates that TN-stage and screening detec-
tion probably do not influence the longer overall survival
for patients with ER-negative tumors and coexisting HS or
AD.
Why AD and HS is associated with a better overall
survival specifically among the ER-negative BC patients
is not known. Compared to ER-positive tumors, the ER-
negative are associated with a poorer prognosis, fewer
treatment strategies and in generally, a worse tumor
grade and hence a more aggressive biological behavior
(Putti et al. 2005). Considering the results from our
study, there seems to be a protective effect from AD or
HS which possibly contributes to decrease the tumor
progression. In a recent study by Calabro et al., it is indi-
cated that lymphocyte infiltrate (LI) is associated withsurvival, but it has opposite effects in ER-positive com-
pared to ER-negative BC patients. A high LI of ER-
positive BC patients was associated with a worse progno-
sis. However, a high LI in ER-negative BC patients was as-
sociated with a better overall survival for these patients. LI
occurs as a reaction of the organism to the growing tumor
mass. Further, Calabro et al., suggest, that the results
might reflect intrinsic differences in the biology of the
breast-tumor subtypes and also a difference in tumor im-
mune surveillance. ER-status seems to be important for
this differentiation (Calabro et al. 2009). This finding
points in a similar direction as our result for the ER-
negative BC patients, in which they both suggest a specific
molecular mechanism through which the immune sys-
tem effectively inhibits growth of ER-negative tumors.
Our suggestion is that LI is higher in AD or HS pa-
tients, compared with patients without these conditions.
Given that our theory is true, another conceivable explan-
ation for our result could therefore be that an ER-negative
BC with a high LI, perhaps caused by an AD or HS, after
Table 3 Cox proportional hazard stratified based on
a) ER-status, and b) menopausal status relating BC patients
with coexisting AD-HS to BC patients without






HR 95% CI for HR p-value HR 95% CI for HR p-value
Lower Upper Lower Upper
AD-HS 0.53 0.30 0.96 0.036 0.98 0.70 1.37 0.909
T1 1.00 Ref Ref 1.00 Ref Ref
T2 1.30 0.95 1.77 0.097 1.60 1.26 2.03 <0.001
T3 2.62 1.69 4.08 <0.001 1.97 1.33 2.91 0.001
T4 3.86 0.91 16.42 0.067 - - - -
N0 1.00 Ref Ref 1.00 Ref Ref
N1 1.63 1.17 2.27 0.004 1.28 1.00 1.64 0.054
N2 2.29 1.51 3.49 <0.001 1.38 0.98 1.93 0.064
N3 2.72 1.54 4.81 0.001 2.61 1.68 4.06 <0.001
Screening 0.59 0.27 1.26 0.174 0.75 0.51 1.11 0.149






HR 95% CI for HR p-value HR 95% CI for HR p-value
Lower Upper Lower Upper
AD-HS 0.63 0.38 1.04 0.073 1.02 0.77 1.34 0.898
T1 1.00 Ref Ref 1.00 Ref Ref
T2 1.22 0.91 1.65 0.190 1.48 1.23 1.78 <0.001
T3 3.29 2.16 5.01 <0.001 1.73 1.25 2.39 0.001
T4 - - - - 1.68 0.53 5.31 0.377
N0 1.00 Ref Ref 1.00 Ref Ref
N1 1.54 1.11 2.13 0.009 1.58 1.28 1.95 <0.001
N2 2.72 1.85 4.00 <0.001 1.84 1.43 2.39 <0.001
N3 3.63 2.07 6.36 <0.001 2.95 2.15 4.05 <0.001
Screening 0.66 0.29 1.50 0.319 0.76 0.59 0.97 0.030
Both models are adjusted for age at BC diagnosis, T- and N-status of the tumor, and
screening simultaneously.
T1 and N0 were reference values for respective category.
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an ER-negative tumor with a low LI. For the ER-negative
tumors, where no satisfactory treatment is available, the
LI serves as an important supplement defense line for the
body.
Possible bias
The patients reported occurrence of AD or HS to the
treating doctor during the interview at time of BC diag-
nosis. There might be some BC patients that omitted to
report or forgot anything of importance for our study.Additionally, it is impossible to know whether there was
a selection bias in the group of patients that perhaps did
not report. In some instances, other data, such as ER-
status, occurrence of metastases, lymph node involve-
ment etc. was missing due to clinical practice at the time
of diagnosis.
ER-status was missing in 34% of all patients (Table 2).
Most missing data was from the patients diagnosed earl-
ier than the mid-nineties, which was before determin-
ation of ER-status was a part of regular clinical practice.
Because the grade of selection is low, this bias factor
should not be too worrying for our result. The patients
diagnosed at the time when ER-status was brought in to
clinical practice can show a selection bias though. At the
start phase, it is possible that ER-status was taken only
on some specially prioritized patients, for example those
with large and aggressively growing tumors or those
with hereditary BC.
The definition of an AD is somewhat fluctuating
which is an issue for discussion. We mainly utilized the
Danish definition from an extensive epidemiological
study in 2007 (Additional file 1: Table S1). This choice
of definition could have meant that some of the diseases
are misclassified. But it should be remembered that this
is an exploratory study, which means that our results
could be due to chance and they need to be validated in
an independent material.
Diabetes and diseases of the thyroid that did not meet
certain criteria as described in Materials and Methods,
were excluded from AD. Therefore, diabetes and thyroid
issues with autoimmune etiology might have been incor-
rectly included and excluded. However, this would only
have weakened our result, which might mean that a
stronger effect exists in reality.
Patients in the southern health care region in Sweden
with BC that need radio- and/or chemotherapy are re-
ferred to the Department of Oncology, Skåne University
Hospital, Lund. However, the region has been changing
slightly during the 1980s and 1990s, but this should not
influence our results significantly. Patients who were not
treated with radio- and/or chemotherapy or who were
too old and weak to receive this treatment and those
whose cancer was too advanced were not remitted to
the Department of Oncology, Skåne University Hospital,
Lund. This means, that the median age is slightly youn-
ger in our material than that of BC patients in general.
In the end, the low median age entails in a result that is
not completely generalizable on all BC patients. In our
study, data collection and treatment of patients, stretches
over a long time span (1980–2010). During this period of
time, criteria for diagnosis and available treatments have
varied, chiefly for BC, but also for AD, which is another
reason why these results needs to be validated in an inde-
pendent material.
Table 4 Cox proportional hazard relating coexistence of a) AD-HS, b) AD, and c) HS to overall survival compared to BC
patients without these comorbidities
a) BC patients with coexisting AD or HS
All patients. N=1508, N=1363 and N=1363.
HR 95% CI for HR p-value
AD-HS, adjusted for: N Lower Upper
Age at diagnosis 194 0.88 0.71 1.10 0.25
Age at diagnosis, TNM-stage 185 0.91 0.72 1.14 0.409
Age at diagnosis, TNM-stage, Screening 185 0.94 0.75 1.18 0.579
Patients younger than 65 years at diagnosis of
BC. N=1021
Patients younger than 50 years at diagnosis of
BC. N=473
N HR 95% CI for HR p-value N HR 95% CI for HR p-value
AD-HS, adjusted for: Lower Upper Lower Upper
Age at diagnosis, TNM-stage 130 0.94 0.75 1.18 0.579 56 0.74 0.48 1.16 0.186
b) BC patients with coexisting AD
All patients. N=1580 and N=1433
N HR 95% CI for HR p-value
AD adjusted for: Lower Upper
Age at diagnosis 122 0.90 0.48 1.16 0.460
Age at diagnosis, TNM-stage 115 0.90 0.69 1.20 0.480
Patients younger than 65 years at diagnosis of
BC. N=1071
Patients younger than 50 years at diagnosis of
BC. N=500
N HR 95% CI for HR p-value N HR 95% CI for HR p-value
AD adjusted for: Lower Upper Lower Upper
Age at diagnosis, TNM-stage 80 0.95 0.66 1.36 0.773 29 0.81 0.45 1.45 0.472
c) BC patients with coexisting HS
All patients included. N= 1632 and N=1363
N HR 95% CI for HR p-value
HS adjusted for: Lower Upper
Age at diagnosis 72 0.85 0.60 1.23 0.388
Age at diagnosis, TNM-stage 70 0.93 0.64 1.34 0.691
Patients younger than 65 years at diagnosis of
BC. N=1101
Patients younger than 50 years at diagnosis of
BC. N=502
N HR 95% CI for HR p-value N HR 95% CI for HR p-value
HS adjusted for: Lower Upper Lower Upper
Age at diagnosis, TNM-stage 50 0.86 0.54 1.37 0.524 27 0.69 0.36 1.33 0.269
The HR shown is for a) AD-HS combined, b) AD, or c) HS adjusted for the variables in the left column.
All analyses were performed using all patients, with an age cutoff at less than 65 years old, and an age cutoff at less than 50 years old for each
group respectively.
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Patients with ER-negative BC had a statistically signifi-
cant better overall survival when they had a history of
AD or a HS. The overall survival was better among
premenopausal patients with AD or HS compared to pa-
tients without AD or HS. These findings need to be vali-
dated in an independent material. If an over-activated
immune system that accompanies a coexisting AD orHS gives a longer survival for BC patients, an immune
activation is a possible future target for treatment, espe-
cially for patients with ER negative tumors and for
young patients.
Ethical standards
This study has been approved by an ethical board and
complies with the current laws of Sweden.
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Additional file 1: Table S1. Diseases generally considered as
autoimmune: thyrotoxicosis, Autoimmune thyroiditis, Insulin dependent
diabetes, Primary adrenocortical insufficiency , Celiac disease, Pernicious
anemia, Autoimmune hemolytic anemia, Idiopathic thrombocytopenic
purpura, Multiple sclerosis, Guillain Barre syndrome, Iridocyclitis,
Wegener’s granulomatosis, Crohn’s disease, Ulcerative colitis, Primary
biliary cirrhosis, Chronic hepatitis, Interstitial cystitis, Endometriosis,
Pemphigoid, Pemphigus, Psoriasis vulgaris, Alopecia areata, Vitiligo,
Seropositive rheumatoid arthritis, Dermatopolymyositis, Myositis,
Polymyalgia rheumatica, Myasthenia gravis, Systemic sclerosis, Systemic
lupus erythematosis, Sjogren’s syndrome.
Abbreviations
AD: Autoimmune diseases; BC: Breast cancer; BMI: Body mass index;
CI: Confidence interval; CTLA-4: Cytotoxic T-Lymphocyte Antigen 4;
ER: Estrogen receptor; HR: Hazard ratio; HRT: Hormonal replacement therapy;
HS: Hypersensitivities; LI: Lymphocyte infiltration; OCP: Oral contraceptive
pills.
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